These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36871111)

  • 1. Evolution of Phase II Oncology Trial Design: from Single Arm to Master Protocol.
    Yu Z; Wu L; Bunn V; Li Q; Lin J
    Ther Innov Regul Sci; 2023 Jul; 57(4):823-838. PubMed ID: 36871111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simon's two-stage design and Bayesian predictive probability monitoring with information sharing across baskets.
    Kaizer A; Zabor E; Nie L; Hobbs B
    PLoS One; 2022; 17(8):e0272367. PubMed ID: 35917296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?
    Parke T; Marchenko O; Anisimov V; Ivanova A; Jennison C; Perevozskaya I; Song G
    J Biopharm Stat; 2017; 27(3):457-476. PubMed ID: 28281911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of two-stage designs of Phase 2 single-arm trials in glioblastoma: a systematic review.
    Yoo W; Kim S; Garcia M; Mehta S; Sanai N
    BMC Med Res Methodol; 2022 Dec; 22(1):327. PubMed ID: 36550391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.
    Mossop H; Grayling MJ; Gallagher FA; Welsh SJ; Stewart GD; Wason JMS
    Br J Cancer; 2022 Feb; 126(2):204-210. PubMed ID: 34750494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
    Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
    Trials; 2014 Feb; 15():68. PubMed ID: 24571662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
    Araujo D; Greystoke A; Bates S; Bayle A; Calvo E; Castelo-Branco L; de Bono J; Drilon A; Garralda E; Ivy P; Kholmanskikh O; Melero I; Pentheroudakis G; Petrie J; Plummer R; Ponce S; Postel-Vinay S; Siu L; Spreafico A; Stathis A; Steeghs N; Yap C; Yap TA; Ratain M; Seymour L
    Ann Oncol; 2023 Jan; 34(1):48-60. PubMed ID: 36182023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Randomized Phase II Trial Designs in Oncology].
    Yoshimura K
    Gan To Kagaku Ryoho; 2018 Nov; 45(11):1561-1566. PubMed ID: 30449838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.
    Berry SM; Broglio KR; Groshen S; Berry DA
    Clin Trials; 2013 Oct; 10(5):720-34. PubMed ID: 23983156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
    Takeda K; Morita S; Taguri M
    Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian two-stage design for phase II oncology trials with binary endpoint.
    Chen L; Pan J; Wu Y; Wang J; Chen F; Zhao J; Chen P
    Stat Med; 2022 May; 41(12):2291-2301. PubMed ID: 35178729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian basket trial design with false-discovery rate control.
    Zabor EC; Kane MJ; Roychoudhury S; Nie L; Hobbs BP
    Clin Trials; 2022 Jun; 19(3):297-306. PubMed ID: 35128970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
    Liu R; Lin J; Li P
    Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.
    Guo B; Li Y
    BMC Med Res Methodol; 2014 Jul; 14():95. PubMed ID: 25074481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.
    Yada S; Hamada C
    Pharm Stat; 2017 Mar; 16(2):114-121. PubMed ID: 27892650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review.
    Meyer EL; Mesenbrink P; Dunger-Baldauf C; Fülle HJ; Glimm E; Li Y; Posch M; König F
    Clin Ther; 2020 Jul; 42(7):1330-1360. PubMed ID: 32622783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial.
    Griffiths G; Fitzgerald R; Jaki T; Corkhill A; Marwood E; Reynolds H; Stanton L; Ewings S; Condie S; Wrixon E; Norton A; Radford M; Yeats S; Robertson J; Darby-Dowman R; Walker L; Khoo S;
    Trials; 2020 Jun; 21(1):544. PubMed ID: 32560744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal adaptive two-stage designs for early phase II clinical trials.
    Shan G; Wilding GE; Hutson AD; Gerstenberger S
    Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian designs with frequentist and Bayesian error rate considerations.
    Wang YG; Leung DH; Li M; Tan SB
    Stat Methods Med Res; 2005 Oct; 14(5):445-56. PubMed ID: 16248347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.